Display and Discovery of Biologics
Imagining the Next-Generation of Biologics
5/10/2027 - May 11, 2027 ALL TIMES EDT
Phage, yeast, and mammalian display have been instrumental for generating therapeutic molecules against a wide range of diseases. The 29th Annual Display and Discovery of Biologics track is the leading track and cornerstone of the PEGS Boston Summit and brings together leaders to showcase emerging technologies and approaches to create novel formats and functionalities. Understanding the role of machine learning and AI to build and navigate repertoires and libraries is at the forefront of the field and accelerating the pace of discovery.
Preliminary Agenda

PLENARY KEYNOTE SESSION

Is AI-Driven Antibody Discovery a Data-Driven Sport?

Photo of Charlotte M. Deane, PhD, Professor, Structural Bioinformatics, Statistics, University of Oxford; Executive Chair, Engineering and Physical Sciences Research Council (EPSRC) , Prof Structural Bioinformatics , Statistics , Oxford University
Charlotte M. Deane, PhD, Professor, Structural Bioinformatics, Statistics, University of Oxford; Executive Chair, Engineering and Physical Sciences Research Council (EPSRC) , Prof Structural Bioinformatics , Statistics , Oxford University

YOUNG SCIENTIST KEYNOTE

Generative Design of Evolution-Resilient Antiviral Biologics

Photo of Pranam Chatterjee, PhD, Assistant Professor, Bioengineering and Computer Science, University of Pennsylvania , Assistant Professor , Bioengineering and Computer Science , University of Pennsylvania
Pranam Chatterjee, PhD, Assistant Professor, Bioengineering and Computer Science, University of Pennsylvania , Assistant Professor , Bioengineering and Computer Science , University of Pennsylvania

Viral evolution can erode the activity of antiviral therapeutics. We integrate evolutionary forecasting with generative molecular design to develop peptides and proteins that remain effective against plausible future variants. Tree-valued Schrödinger bridge matching (TreeSBM) predicts branching evolutionary trajectories and their uncertainty. PROPHET, our multi-objective discrete flow model, then uses these forecasts to generate and optimize biologics for target engagement, therapeutic properties, and robustness across predicted futures. I will present unpublished pseudoviral infection data demonstrating functional envelope variants predicted by TreeSBM and PROPHET-designed peptides that block infection by later variants of concern and interest, using only earlier viral sequences for design.

QUANTITATIVE YEAST DISPLAY: GETTING NUMBERS OUT OF SELECTION

KEYNOTE PRESENTATION: Multivalent VLP Reagents for Detecting Weak Interactions in Yeast Display

Photo of Michael E. Birnbaum, PhD, Assistant Professor, Biological Engineering, Massachusetts Institute of Technology , Asst Prof , Biological Engineering , Massachusetts Institute of Technology
Michael E. Birnbaum, PhD, Assistant Professor, Biological Engineering, Massachusetts Institute of Technology , Asst Prof , Biological Engineering , Massachusetts Institute of Technology

To better study protein-protein interactions, we developed VelociRAPTR, a scalable library-on-library screening platform that measures millions of T cell receptor (TCR)–peptide–MHC interactions in parallel. Systematic perturbation of both sides of the interface revealed mutations that tune affinity, restrict specificity, or broaden recognition, exposing general principles of molecular recognition. More broadly, this approach enables large-scale mapping of protein interaction landscapes to guide engineering of proteins with defined specificity profiles.

Linking Sequence to Function via High-Throughput Biochemistry

Polly M. Fordyce, PhD, Assistant Professor, Genetics, Stanford University , Asst Prof , Genetics , Stanford Univ

Selection of Agonist and Antagonist Nanobodies Targeting G Protein-Coupled Receptors

Photo of Andrew C. Kruse, PhD, Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School , Professor , Department of Biological Chemistry and Molecular Pharmacology , Harvard Medical School
Andrew C. Kruse, PhD, Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School , Professor , Department of Biological Chemistry and Molecular Pharmacology , Harvard Medical School

G protein coupled receptors (GPCRs) are the largest class therapeutic drug targets in humans. Using epitope-directed yeast display selections and computational screens we identified agonist and antagonist camelid VHH antibody fragments (’nanobodies’). These serve as functional modulators and components for building multispecific binders.

Presentation to be Announced

PROTEIN DEGRADERS

From Repertoire Discovery to Programmable Biologics

Photo of Yi Shi, PhD, Associate Professor, Protein Engineering, Icahn School of Medicine, Mount Sinai , Associate Professor , Pharmacological Sciences , Icahn School of Medicine at Mount Sinai
Yi Shi, PhD, Associate Professor, Protein Engineering, Icahn School of Medicine, Mount Sinai , Associate Professor , Pharmacological Sciences , Icahn School of Medicine at Mount Sinai

We have developed integrated proteomics and AI-enabled platforms to discover and structurally characterize large nanobody repertoires at scale. I will discuss how these technologies can rapidly identify functional binders and map their epitopes, and how selected nanobodies can be engineered into multispecific/multivalent constructs for targeted receptor modulation and payload delivery.

Next-Generation Degrader Antibody Conjugates

Photo of Chad May, PhD, CSO, Orum Therapeutics , CSO , Orum Therapeutics
Chad May, PhD, CSO, Orum Therapeutics , CSO , Orum Therapeutics

Our next-generation Degrader Antibody Conjugates (DACs) are designed to improve safety and efficacy through advanced antibody and linker engineering. DACs combine the tissue selectivity of antibody-mediated delivery with the well-validated catalytic mechanism of targeted protein degradation. DACs offer opportunities to expand beyond conventional cytotoxic ADC payloads.

EpiTACs Bispecific Antibodies Degrade Extracellular Targets to Overcome Limitations of Current Antibody Therapeutics

Photo of Shyra J. Gardai, PhD, CSO, EpiBiologics , CSO , EpiBiologics
Shyra J. Gardai, PhD, CSO, EpiBiologics , CSO , EpiBiologics

EpiBiologic’s EpiTAC bispecific antibodies are a different therapeutic approach that can degrade receptor tyrosine kinases (RTKs) independent of their form. Removal of the oncogenic RTK and associated scaffolding function is differentiated from standard blocking approaches. Tissue-selective EpiTACs can degrade EGFR, cMET, and cKIT to drive deep and prolonged anti-tumor activity independent of form. EpiTACs have the potential to redefine monotherapy and combination therapies. EPI-326 is a novel tissue selective EGFR approach that could address the limitations of current EGFR drugs. A phase I study of EPI-326 in patients with advanced/metastatic HNSCC and mutant EGFR NSCLC is ongoing.

NovoFy—Designing the Inaccessible: Generative Minibinders for Intracellular Targets

Photo of Fernando Garces, PhD, Co-Founder and CEO, BioGlyph , Co-Founder and CEO , BioGlyph
Fernando Garces, PhD, Co-Founder and CEO, BioGlyph , Co-Founder and CEO , BioGlyph

Generative design of miniproteins opens a new route to intracellular targets long seen as out of reach for biologics. NovoFy is a physics-driven AI platform that generates minibinders: stable, selective, and format agnostic proteins built to bind medical targets with a developable profile. Pairing affinity with developability yields drug leads, not binders alone, and expands proximity-based modalities such as BioTACs and RIPTACs, enabling new mechanisms via precise target recognition in living cells.

INCORPORATING PROTEIN DYNAMICS INTO SELECTION AND DESIGN

Where’s the Big Data for Protein Dynamics?

Photo of Hannah Wayment-Steele, PhD, Assistant Professor, Biochemistry, University of Wisconsin-Madison , Assistant Professor , University of Wisconsin Madison
Hannah Wayment-Steele, PhD, Assistant Professor, Biochemistry, University of Wisconsin-Madison , Assistant Professor , University of Wisconsin Madison

Predicting protein motions is one of the next grand challenges for structural biology. This talk will discuss recent efforts combining datasets from NMR spectroscopy with large language models towards this end.

Cryptic Pockets: From Serendipity to Intentional Discovery and Targeting

Photo of Greg Bowman, PhD, Louis Heyman University Professor, University of Pennsylvania
Greg Bowman, PhD, Louis Heyman University Professor, University of Pennsylvania

Targeting cryptic pockets that open due to protein dynamics could open new opportunities for drug discovery that aren’t apparent from known protein structures. However, these pockets are often only found by serendipity. Here, I’ll discuss progress in combining molecular dynamics simulations, biophysical experiments, and AI-based protein design to intentionally identify and target cryptic pockets.

Computational Design of pH-Responsive Proteins

Photo of Green Ahn, PhD, Assistant Professor, Chemistry, University of Washington , Assistant Professor , Chemistry , University of Washington
Green Ahn, PhD, Assistant Professor, Chemistry, University of Washington , Assistant Professor , Chemistry , University of Washington

pH gradients are central to physiology, from vesicle acidification to the acidic tumor microenvironment. I will describe two complementary principles and associated computational methods for designing pH-dependent binders: (i) introducing histidine residues adjacent to positively charged residues at interfaces to induce electrostatic repulsion and weaken binding at low pH, and (ii) introducing buried histidine-containing charged hydrogen-bonding networks in the binder core such that the protein is destabilized under acidic conditions. Our methods should be broadly useful for designing pH-responsive protein therapeutics.

NEW TECHNOLOGIES IN DISPLAY AND DISCOVERY

Screening Macrocyclic Peptide Libraries by Yeast Display Allows Control of Selection Process and Affinity Ranking

Photo of Sara Linciano, PhD, Umberto Veronesi Postdoctoral Fellow, European Center for Living Technology, Italy , Post-Doc Researcher , Department of Molecular Sciences and Nanosystems , Ca' Foscari University
Sara Linciano, PhD, Umberto Veronesi Postdoctoral Fellow, European Center for Living Technology, Italy , Post-Doc Researcher , Department of Molecular Sciences and Nanosystems , Ca' Foscari University

Macrocyclic peptides bridge the gap between small molecules and biologics, serving as powerful modalities for drug discovery. We present a yeast display platform combining flow cytometry and next-generation sequencing to quantitatively screen millions of variants with real-time monitoring of binding parameters. We will highlight recent technological advancements, the discovery of macrocyclic ligands against diverse proteins, and their biophysical characterization.

Phage Display Enables Machine Learning Discovery of Cancer Antigen-Specific TCRs

Photo of Giancarlo Croce, PhD, Postdoctoral Researcher, Oncology, University of Lausanne , ML Scientist/Postdoctoral Researcher , Oncology , IMPRINT / Univ of Lausanne
Giancarlo Croce, PhD, Postdoctoral Researcher, Oncology, University of Lausanne , ML Scientist/Postdoctoral Researcher , Oncology , IMPRINT / Univ of Lausanne

T cells targeting epitopes in infectious diseases and cancer play a central role in spontaneous and therapy-induced immune responses. Starting from a T cell receptor (TCR) targeting the cancer-testis antigen NY-ESO-1, we generated large phage-display libraries of randomized TCRs. Leveraging these data, we trained a machine-learning predictor of TCR–epitope interactions and used it to identify additional NY-ESO-1–specific TCRs from TCR repertoires. Cellular assays confirmed that the predicted TCRs were functional against NY-ESO-1, with no detectable cross-reactivity. Our work demonstrates how combining display technologies with machine-learning models of TCR–epitope recognition can enable the efficient discovery of antigen-specific TCRs from large immune repertoires.


For more details on the conference, please contact:
Christina Lingham
Executive Director, Conferences and Fellow
Cambridge Healthtech Institute
Phone: 508-813-7570
Email: [email protected]

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Email: [email protected]

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-1340
Email: [email protected]


Register

View By:


Premier Sponsors

Biointron_new       Kactus